Get started
Author

Nieves Díaz

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome
2020 · Maria Juarez, Nieves Diaz, et al. · Lara D. Veeken · 49
PDF
Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies
2020 · Nieves Diaz, Maria Juarez, et al. · The Journal of Immunology · 34
Patients’ perception of cancer-related fatigue: results of a survey to assess the impact on their everyday life
2008 · Nieves Díaz, Salvador Menjón, et al. · Clinical & Translational Oncology · 34
PDF
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
2025 · María Gion, Isabel Blancas, et al. · Nature Medicine · 32
PDF
Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens
2018 · I. Blancas, E. Aguirre, et al. · Clinical & Translational Oncology · 12
Abstract PS16-02: Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
2024 · Maria Gion, Patricia Cortez-Castedo, et al. · Cancer Research · 8
A Dual‐Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [14C]Seletalisib (UCB5857) in Healthy Subjects
2017 · Eric Helmer, Jean‐Marie Nicolas, et al. · The Journal of Clinical Pharmacology · 8
Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia
2011 · Aurelia Bustos, Ruth Álvarez, et al. · Current Medical Research and Opinion · 7
Efficacy and safety of oral vinorelbine (NVBO) in first- or second-line metastatic breast cancer (MBC).
2010 · I. Blancas, S. Morales, et al. · Journal of Clinical Oncology · 7
Abstract CT114: Data from first-in-human study of EXS21546, an A2A receptor antagonist, now progressing into phase 1 in RCC/NSCLC
2023 · Nieves Diaz, Holly Garratt, et al. · Cancer Research · 6
Ab0458 a Phase Ii Randomised, Double-blind, Placebo-controlled, Proof of Concept Study of Oral Seletalisib in Patients With Primary Sjögren's Syndrome (pss)
2019 · Maria Juarez, Nieves Diaz, et al. · Annals of the Rheumatic Diseases · 5
PDF
Ensayo piloto con el anticuerpo monoclonal ior-C5 como agente potencial de la inmunocentelleografía del cáncer colorrectal
2001 · J.P. Oliva, G. Pimentel, et al. · Revista Española de Medicina Nuclear · 4
A phase II randomised, double-blind, placebo-controlled, proof of concept study of oral seletalisib in patients with primary Sjögren’s syndrome (PSS).
2019 · Juárez, Maria, Diaz, Nieves, et al. · HAL (Le Centre pour la Communication Scientifique Directe) · 3
Radioinmunolocalización de tumores de cabeza y cuello con un nuevo anticuerpo monoclonal contra el receptor del EGF. Resultados preliminares
2004 · J.P. Oliva, T. Cruz, et al. · Revista Española de Medicina Nuclear · 2
Safety and Tolerability of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory/Relapsed Follicular Non Hodgkin Lymphoma. Preliminary Data from the Pearl Study.
2005 · Nieves Díaz, Э А Османов, et al. · Blood · 1
Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results
2019 · J. Salvador, E.M. Ciruelos, et al. · Annals of Oncology
PDF
Association between serum levels of C-reactive protein and response to treatment of chemotherapy-induced anemia in patients with solid tumors: a multicenter, prospective, observational study
2013 · Gaspar Esquerdo Galiana, Jose Manuel Cervera, et al. · Medical Oncology
Efficacy and safety of weekly oral vinorelbine (NVBO) as single agent in first- or second-line metastatic breast cancer (MBC).
2012 · Serafin Morales, Isabel Blancas, et al. · Journal of Clinical Oncology
Clinical experience with oral vinorelbine (NVBO) plus prednisone as first- or second-line chemotherapy of metastatic hormone-refractory prostate cancer (HRPC).
2012 · Jose Manuel Cervera Grau, Miguel Beltran, et al. · Journal of Clinical Oncology
Observational study to evaluate the possible association between serum levels of C-reactive protein and response to the treatment of chemotherapy-induced anemia in solid tumors (Pronost Study).
2010 · G. Esquerdo, J. Cervera, et al. · Journal of Clinical Oncology
Clinical experience with oral vinorelbine (NVB) plus prednisone as first- or second-line chemotherapy of metastatic hormone- refractory prostate cancer (HRPC)
2009 · J. M. Cervera, I. Garcia-Carbonero, et al. · Journal of Clinical Oncology
Radio-immunodetection of colorectal cancer using Tc-99m labeled monoclonal antibody ior-CEA1: Results of a phase III clinical trial
2005 · JP Oliva, Gilmara Pimentel, et al. · World Journal of Nuclear Medicine
Works count: 22
Citation count: 212
H-index: 7
I10-index: 5
Year
Topic
Type